Thomas Swan Appoints Keith Wiggins as Non-Executive Chairman

Thomas Swan announced the appointment of Keith Wiggins as its non-executive...
Thomas Swan announced the appointment of Keith Wiggins as its non-executive chairman. Source: Thomas Swan

Thomas Swan announced the appointment of Keith Wiggins as its non-executive chairman. He will join the board on the Feb. 19, 2019.

As the former president and managing director of Dow UK, Eire & Nordic, past president of the Chemical Industries Association (CIA) and more recently as the COO and executive board member of Nanoco Group, Wiggins has considerable experience and knowledge from a career that has spanned 30 years in the chemical industry.

Commenting on Keith’s appointment, Harry Swan, CEO and owner of Thomas Swan said: “I’m delighted that Keith has agreed to chair our company. I’ve worked with him over a number of years at the Chemical Industries Association and on the steering group of the Chemistry Growth Partnership, now known as the Chemistry Council, and I know he is going to be an excellent Chairman. Keith’s unique experience in both large multinationals and smaller highly innovative companies is ideal as we look to grow Thomas Swan in the UK and overseas.”

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.